BCL2L1 and diffuse large B-cell lymphoma: In addition, except for ibrutinib and sotrastaurin treatment of LY3 (as expected), treatment with these BCR signalosome inhibitors substantially reduced expression of the NF-κB target and pro-survival protein BCL-XL in the ABC-DLBCL cell lines (Fig. 3B and Supplementary Fig. 2).